Pivekimab sunirine

The kidney injury, when it occurs, is a consequence of the treatment context rather than direct tubular toxicity from the conjugate. Two mechanisms dominate. First, tumor lysis: BPDCN and CD123-positive acute leukemias are proliferative, lysis-prone diseases, and rapid killing of a large blast mass releases potassium, phosphate, and purines, with uric acid and calcium-phosphate precipitating as intratubular crystals to cause tumor-lysis AKI (Howard, Nat Rev Dis Primers 2024). Second, capillary-leak physiology: CD123-directed agents can trigger a systemic capillary-leak syndrome — endothelial activation with hypoalbuminemia, third-spacing, edema, and hypotension — that reduces effective circulating volume and renal perfusion, producing prerenal and, if sustained, ischemic tubular injury. This mechanism is best characterized for the CD123 immunotoxin tagraxofusp, which carries a capillary-leak warning (Pemmaraju, NEJM 2019; JCO 2022) and is imported here as a class consideration for CD123-targeting therapy rather than as an established pivekimab-specific effect. Pivekimab's own documented dose-limiting event was reversible hepatic veno-occlusive disease — a sinusoidal endothelial injury that signals endothelial vulnerability but is hepatic, not renal (Daver, Lancet Oncol 2024). The antibody-drug conjugate is a large molecule catabolized by reticuloendothelial/lysosomal proteolysis, not cleared by glomerular filtration, so the kidney is a victim of the setting, not the elimination organ.

AKI presents within a systemic syndrome, not in isolation. With tumor lysis, uric acid, phosphate, potassium, and LDH rise while calcium falls within days of effective cytoreduction, sometimes with arrhythmia, cramps, or oliguria. With capillary leak, the patient develops weight gain, edema, hypoalbuminemia, and hypotension, and the kidney injury appears as oliguria and a rising creatinine tracking the intravascular volume depletion. Infusion-related reactions, cytopenias, and infection are common in this heavily pretreated population and can independently contribute to hemodynamic or septic AKI.

Management is directed at whichever syndrome is driving the injury. For tumor lysis: aggressive IV hydration, rasburicase for significant hyperuricemia (allopurinol for lower-risk prophylaxis), medical management of hyperkalemia and hyperphosphatemia, and correction of calcium only if symptomatic. For capillary-leak-related prerenal AKI: careful volume support to restore perfusion, albumin as indicated, close attention to oxygenation and hemodynamics, and treatment/interruption per the drug's capillary-leak guidance; over-resuscitation into a leaky vasculature is itself harmful, so titrate to perfusion and urine output. Provide standard supportive AKI care, avoid additional nephrotoxins, and treat intercurrent infection. Escalate to renal replacement therapy for refractory tumor-lysis metabolites, volume overload, or oliguric AKI unresponsive to medical measures. Hold or delay pivekimab per protocol for significant capillary leak, tumor lysis, or organ toxicity.Lesion-level management framework

No pharmacokinetic renal dose adjustment is defined. Pivekimab sunirine is an antibody-drug conjugate whose antibody scaffold is cleared by reticuloendothelial/lysosomal catabolism rather than glomerular filtration, so creatinine clearance is not expected to change drug exposure, and dedicated data in severe renal impairment or dialysis are limited. Dose modification is driven by hematologic and organ toxicity (notably the veno-occlusive-disease and infusion-reaction signals) and by tumor-lysis/capillary-leak events, not by baseline GFR. Pre-existing CKD raises the risk of tumor-lysis and hemodynamic AKI and warrants intensified prophylaxis and monitoring rather than a milligram-level renal dose change.

Not dialyzable — a full-size antibody-drug conjugate vastly exceeds any dialysis-membrane cutoff and stays in the vascular/interstitial compartment, so hemodialysis does not remove the drug. As with other large biologics, renal replacement therapy remains a legitimate tool for the metabolic consequences (tumor-lysis potassium, phosphate, uric acid) and for oliguric AKI or volume overload — it clears the complications, not the conjugate.

The task is to attribute AKI to the right driver. Tumor-lysis crystal nephropathy is favored by hyperuricemia, hyperphosphatemia, hyperkalemia, high LDH, and a falling calcium within 1–3 days of effective cytoreduction. Capillary-leak prerenal AKI is favored by weight gain, edema, hypoalbuminemia, and hypotension without an active urine sediment, responding to perfusion support. Both must be distinguished from sepsis-associated AKI (common in this cytopenic, heavily pretreated population), from concomitant nephrotoxin or contrast exposure, and from pre-existing CKD. Unlike platinum agents, this is not a primary proximal-tubular toxin — an isolated Fanconi or bland slowly progressive creatinine rise points elsewhere.